Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)
Felix Popp(University of Regensburg), Marc H. Dahlke(Robert Bosch Hospital), Philipp Renner(Robert Bosch Hospital), Johannes Dillmann, Andreas A. Schnitzbauer(American Institute of Biological Sciences), Edward K. Geissler(University Hospital Regensburg), Cheryl A Graveen(Athersys (United States)), Volker Benseler(University of Regensburg), James A. Hutchinson(University Hospital Regensburg), Florian Zeman(University Hospital Regensburg), Martin J. Hoogduijn(Erasmus MC), Hans J. Schlitt(University Hospital Regensburg), Michael Koller(University Hospital Regensburg), Barbara Fillenberg, Elke Eggenhofer(University Hospital Regensburg), Robert Deans(Rubius Therapeutics (United States)), Deborah Ladenheim(Athersys (United States))
Cited by 51
Related Papers
Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings
|Annals of Surgery|2012|1.3k
Banff Schema for Grading Liver Allograft Rejection: An International Consensus Document
|Hepatology|1997|1.3k
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion
|Frontiers in Immunology|2012|820
Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services
|British journal of surgery|2020|719
Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs
|Frontiers in Immunology|2019|696